Duopharma Biotech records strong growth in Q3 FY2024
Duopharma Biotech Berhad reported robust growth for Q3 FY2024, with revenue reaching RM208.73 million, pushing cumulative revenue for the year to RM620.02 million—a 15.4% increase year-on-year. The company also saw a cumulative profit before tax (PBT) increase of 11.3% and profit after tax (PAT) rise by 7.7%. This growth was largely driven by higher sales, especially in the public health sector, which balanced rising costs from the new K3 facility and increased financing expenses.
The company’s strategic focus on internal efficiencies and cost management continues to pay off. With the Malaysian government’s recent 10% healthcare budget increase, Duopharma sees a positive outlook for demand in public health supplies.
Additionally, two Duopharma subsidiaries received five new Letters of Offer to supply products to government facilities until December 2026, adding an estimated RM87.66 million to the order book. Duopharma also issued an interim dividend of 1.0 sen per share, totaling RM9.62 million for shareholders.
Read More News on Business News Malaysia
Read More News on Business News Malaysia
Strong interest highlights importance of major infrastructure development.
Temporary shortage highlights importance of supply chain resilience.
Backdoor attacks targeting businesses in Malaysia surged by 86% year-on-year in 2025 – the highest…
Kawan Renergy's subsidiary secured a RM70.4m order for diesel generators, boosting its orderbook and marking…
Public Investment Bank's strategy highlights market support from liquidity, but notes global economic fragility amid…
BTL Industries unveils six medical devices, including EXOMIND for mental health, advancing rehabilitation, mobility, and…
This website uses cookies.